Proliferating cell nuclear antigen (PCNA) was evaluated as a marker of cell proliferation in formalin-fiied rat liver tissue through a comparative study with the thymidine analogue 5-bromo-Zdeoxyudine (BrdU). The comparison was conducted through the introduction of a dual immunohistochemical procedure that allows the simultaneous detection of the two antigens. The results of this study suggest that although statistically similar indexes for each can be achieved, what has been reported to be the "S-phase fraction" of PCNA-labeled nuclei is significantly different from the population of cells marked by BrdU. The data also suggest that the reason for this difference is that the "S-phase fraction" of PCNA-labeled nuclei is the population of cells in late GIand early S-phases. BrdU, by comparison, is incorporated into cells only during DNA synthesis. Therefore, although BrdU and PCNA labeling techniques may both be effective for evaluating cell proliferation rates, it must be recognized that labeling indim derived from each are not entirely synonymous. The method presented here for the simultaneous labeling of PCNA and BrdU antigens may have utility in studies of cell cycle p e r t u r b a t i o n s . ( j H e m Cytochem 41:1-6, 1993) 
Introduction
Proliferating cell nuclear antigen (PCNA) is a 36 KD auxiliary protein to DNA polymerase-S (1,2), which is found in various concentrations within the cell throughout the cell cycle and in greatest quantities during S-phase (3). The use of a monoclonal antibody to PCNA for examining cell proliferation in fixed embedded tissues has been recommended as an alternative to DNA-incorporated tritiated thymidine (4,5) and 5-bromo-2'-deoxyuridine (BrdU) ( 5 ) . Its potential applications are wide-ranging in the fields of diagnostic oncology and toxicology. In particular, the introduction of a commercially available microwave-based system for retrieving antigens in formalin-fixed tissues (6), shown to be effective with respect to PCNA (7) , could open many possibilities in the study of cell proliferation in archival tissue. Although the use of an anti-PCNA antibody in determining indices of cell proliferation has been shown to correlate well with tritiated thymidine in methanol-fixed tissues (4), its use in measuring labeling indices in formalin-fixed tissues has been questioned because of the labeling of non-S-phase nuclei (4, 8) . It has been reported that two populations of PCNA are recognized by the 19A2 antibody: one closely associated with and tightly bound to DNA replication sites in chromatin, and a second which is nucleoplasmic and chromatin-associated (4, 9) . Fixation in formalin preserves both populations of PCNA, whereas methanol fixation preserves only the former (4, 9) . Therefore, fixation in methanol allows marking only of that portion of nuclei undergoing DNA synthesis (S-phase), whereas fixation in formalin results in the staining of nuclei in GI, S, and G2 phases (4).
There appear to be two theories with respect to the time of peak concentration of PCNA within the cell cycle. One suggests that cellular PCNA content peaks during late G1 or early S-phase (6, 10, 11, 12) , while a second suggests that synthesis begins in late GI and peaks during S-phase (3, 5, 13) . Recent methods used the later hypothesis as a basis to differentiate between S-phase and non-S-phase PCNA-positive nuclei in formalin-fixed tissues (5,7). If in determining a PCNA labeling index one counts only those nuclei thought to be in S-phase (stained intensely throughout the nucleoplasm), it is believed that the fraction of labeled nuclei should be similar to results achieved through the use of a monoclonal antibody to detect DNA-incorporated BrdU (5).
BrdU is a conventional marker of S-phase DNA synthesis and labeling indices derived using BrdU have been shown to be comparable to those obtained with tritiated thymidine (14J5). The purpose of the present studies was to develop a PCNA-BrdU dual-stain procedure to be used in conjunction with the respective single stains on formalin-fixed rat liver tissue to obtain hepatocyte proliferative labeling indices that allow direct comparison of the population of nuclei marked by each of the two antibodies. In contrast to previous comparative studies on cultured cell lines @,lo), the present study is an in vivo model in which PCNA-positive, BrdUpositive, and PCNA-BrdU-positive nuclei are easily identifiable and can be simultaneously visualized and evaluated in intact paraffin-embedded tissue. Furthermore, the method employs simple microscopy, obviating the need for autoradiography or immunofluorescence.
Materials and Methods
TissueS. One CrlCD BR rat weighing approximately 250 g was injected intraperitoneally with 12Omglkg of a 2.4% solution of BrdU in physiological saline. A single rat was used to avoid interanimal variability in the results.
The hepatocyte proliferation labeling index (percent of hepatgrtes labeled positively for BrdU) for this animal, approximately 0.7%. was within laboratory historical controls for a 2-hr pulse label. After 2 hr the animal was sacrificed by injection with sodium pentobarbital and exsanguination. The liver was removed, fixed in 10% buffered formalin for 24 hr, and transferred to 70% ethanol. Lobes of liver were trimmed to approximately 2 mm and processed. Processed tissues were then embedded in paraffin, sectioned at 5 Bm, and mounted on Vectabond-coated slides (Vector Laboratories; Burlingame, CA). Animals were used and cared for according to the guidelines of this AALAS-accredited institution.
Immunocytochemistry. The method of Greenwell et al. (7) was used, with some modifications, on 15 sections from the same block of tissue. Five sections were stained for BrdU, five for PCNA, and five were simultaneously stained for PCNA and BrdU. The tissue sections were deparaffinized and rehydrated through a graded series of alcohols to distilled water. A periodic acid endogenous peroxidase block (Kirkegaard & Perry; Gaithersburg, MD) was applied for a period of 4 min. Sections were placed in plastic Coplin jars filled with a commercial solution containing less than 1% lead(II1)thiocyanate (Biogenex; San Ramon, CA) diluted 1:4 with deionized water. The Coplin jars were microwaved at 80% of full power (approximately 720 W i n a 900-W microwave) for 2 min, allowed to cool for 1 min, and microwaved for a second 2-min interval at 80% of full power. After cooling for 10 min, sections were rinsed in distilled water and air-dried.
The dried sections were circled with a hydrophobic PAP pen and rinsed twice (5 min each) in Automation buffer (Biomeda; Foster City, CA), pH 7.5, diluted 1:lO. Diluted buffer containing 1% non-fat dried milk (Acme Markets; Malvern, PA) was used in the subsequent block and antibody dilutions. Negative charge was blocked by a 20-min application of normal goat serum (Vector Laboratories) diluted 1:20. The primary anti-PCNA IgM antibody clone l9A2 (Coulter Immunology; Hialeah, FL) diluted 1:3200, was applied to PCNA single-stain and to dual-stain sections for a period of 24 hr. Sections were rinsed once for 5 min and once for 1 hr in diluted buffer. On PCNA single-stain sections the anti-PCNA IgM antibody was applied at a dilution of 1:3200 for a period of 1 hr. On BrdU single-stain sections the anti-BrdU IgG (Becton Dickinson; San Jose, CA) antibody was applied at a dilution of 1:50 for a period of 1 hr. On dual-stain sections the anti-PCNA IgM and anti-BrdU IgG antibodieswere applied in combination at dilutions of 1:3200 and 1:50, respectively. Negative control slides were also run with normal mouse IgG substituted for the primary antibodies during both primary antibody incubations. After two rinses in buffer, p-chain-specific biotin-SP-conjugated goat anti-mouse IgM (Jackson Immunological Research; West Grove, PA) was applied in combination with Fc fragment-specific alkaline phosphatase-conjugated goat anti-mouse IgG (Jackson Immunological Research) at dilutions of 1:200 and 1:100, respectively, for a period of 30 min to all sections. The sections were rinsed in two changes of buffer. Peroxidase-conjugated streptavidin (Biogenex) was applied at a dilution of 1:lO to PCNA single-stain and to dual-stain sections. After two rinses in buffer and a rinse in distilled water, Histomark Blue (Kirkegaard & Perry) was prepared according to the manufacturer's instructions and applied to BrdU single-stain and dual-stain sections for a period of 32 min. Sections were rinsed once in distilled water, twice in buffer, and once again in distilled water. 3-Amino-9-ethylcarbazole (Vector Laboratories) was prepared according to the manufacturer's instructions and applied for a period of 30 min to PCNA single-stain and dual-stain sections. All sections were rinsed in distilled water and counterstained for 45 seconds in Mayer's hematoxylin. Crystal Mount (Biomeda), an aqueous mounting medium, was applied, slides were dried at 80°C for 20 min. dipped in xylene, and coverslipped with Permount (Fisher Scientific; Fair Lawn, NJ). Crossreactivity and specificity were checked for both the single-and dual-stain methods by running control sections that lacked the primary, link, or label antibodies. In addition, control sections were run in which one of the two primary antibodies was omitted and all link and label antibodies were applied. The substrate associated with the primary antibody that was omitted was then applied. No significant background staining was seen, nor was there any crossreactivity between the two labeling systems.
Scoring of PCNA-and BrdU-labeled Nuclei. A non-traditional labeling index (defined here as labeling score) was determined by examining 500 random fields at x 1000 magnification and scoring the number of labeled nuclei. On BrdU single-stain sections, all nudei exhibiting the stain, regardless of its intensity, were considered labeled. Scoring of PCNA nuclei thought to be in S-phase was done in accordance with the guidelines outlined by Foley et al. (5) . whereby only those nuclei exhibiting an intense and uniform red to deep-red nuclear stain were considered positively labeled. On dual-stain sections the criteria for assessing nuclei exhibiting stain for one of the two antigens was the same as on individual sections. In contrast, all nuclei staining positively for both antigens, regardless of their intensity, were considered PCNA-BrdU positive. This criterion was used because of the difficulty in judging the PCNA content of PCNA-BrdU-positive nuclei. as negative controls. The BrdU-positive nuclei ranged in color from light to dark violet, with a speckled to uniform staining pattern (Figure 1) . PCNA nudear ranged in color from light pi& to an intense deep red, with staining patterns ranging from speckled to uniform (Figure 2 ). In addition, speckled cytoplasmic stain for PCNA was observed and was particularly noticeable in mitotic
Results
Nuclear staining was observed on all sections except for those run Refer to Materials and Methods for scoring criteria. Not statistically different from the mean of the BrdU single-stain sections.
Statistically different from the mean of the total PCNA on dual-stain sections (p<O.Ol).
Refer to t a t for discussion. Table 1 for column designations. b This value slightly overcstimatn the m e ratio, since "a" includes the small number of BrdU-labeled nuclei in GI (see "c" in Table 1 ) as well as those in S-phase.
figures. BrdU-positive nuclei and PCNA-positive nuclei, were observed on dual-stain sections. PCNA-BrdU-positive nuclei were also easily identifiable, with variable amounts of each of the two stains present. Some nuclei were intensely stained for BrdU with lightpink PCNA stain present, whereas other nuclei were intensely stained for PCNA with light BrdU staining (Figures 3 and 4) . Nuclei with roughly equal staining for both antigens were also present, with each of the two stains ranging in intensity from weak to strong (Figure 5) .
Labeling scores for PCNA and BrdU on single-stain sections were not statistically different ( Table 1) . This similarity is reflected in the 1.12 ratio of BrdU to PCNA labeling scores ( Table 2) . The PCNA or BrdU labeling score on dual-stain sections is the total number of cells staining positively for both PCNA or BrdU, plus those staining positively for PCNA alone or BrdU alone, respectively. The labeling score for BrdU on single-stain sections was not statistically different from the BrdU labeling score obtained from dual-stain sections ( Table 1 ). The two scores were in a ratio of 0.93 ( Table 2 ). In contrast, the labeling score for PCNA on dual-stain d o n s was statistically different from the PCNA labeling score obtained from singlestain sections ( Table 1) . These two scores were in a ratio of 0.56 ( Table 2 ). The BrdU labeling score from dual-stain sections was statistically different from the PCNA labeling score from dual-stain sections (Eble 1). These two scores were in a ratio of 0.68 (Eble 2).
Discussion
The results of this comparative study of BrdU and PCNA labeling methods in rat hepatocytes, employing single-stain and dual-stain sections, suggest that what has been reported to be the "S-phase fraction" of PCNA-positive nuclei is significantly different from the portion of nuclei labeled by BrdU, in spite of their statistically similar labeling scores. The results are consistent with the notion that those nuclei stained uniformly and intensely for PCNA are in fact in late G1 and early S-phases (10). whereas positive BrdU staining is present only in cells that entered or passed through S-phase during the BrdU dosing period.
Previous work has demonstrated that the PCNA antigen is present in non-S-phase cells in formalin-fixed tissues (4.8). However, on the basis of the hypothesis that PCNA is in peak concentration during S-phase (3,5,12), those nuclei exhibiting high PCNA content (i.e., uniform and intense red nuclear stain) were counted. It is recognized that there is some subjectivity involved in detecting weak vs intense PCNA labeling. Several methodological measures were taken to facilitate the differentiation of uniform and intense red nuclear stain from minimal or diffuse pink nuclear stain. The first involved reducing the concentration of the PCNA antibody (16) relative to earlier methods (5,7), in conjunction with increasing its incubation period from 1 hr to a total of 25 hr. In addition, a p-chain-specific secondary antibody was introduced (16), which dramatically reduced the amount of nonspecific background stain over that obtained when a universal IgG link was used. This modification also increased the contrast between labeled and non-labeled nuclei and facilitated our ability to introduce a dual-stain procedure. The high specificity of the anti-p-chain antibody allowed simultaneous application of the two labeling systems without any crossreactivity.
PCNA and BrdU labeling scores, which were not statistically different, were obtained from single-stain sections. Although this result is consistent with the hypothesis of Foley et al. ( 5 ) (i.e., that it is possible to accurately differentiate between S-phase and non-S-phase PCNA-positive nuclei in formalin-fiied tissues), dual-stain sections in which the two stains could be simultaneously identified in separate nuclei made it apparent that the labeling methods were marking distinctly different populations of nuclei, in spite ofthe statistical similarity of the labeling scores obtained from singlestain sections. This conclusion was drawn from the large number of nuclei positive for PCNA only on dual-stain sections, not from the statistically different PCNA labeling scores on single-stain and dual-stain sections. The different PCNA labeling scores on singleand dual-stain sections merely reflect our inability to assess the PCNA content of PCNA-BrdU-positive nuclei and the resulting need to use different PCNA scoring criteria on single-and dualstain sections. On average, approximately 43.2% (Eble 2) of the PCNA-BrdU-positive nuclei would not meet the criteria to be considered labeled ifthey were examined individually for PCNA. The existence of the two different populations and the knowledge that BrdU is an S-phase marker lead to the conclusion that the uniform red PCNA-labeled nuclei are not necessarily in S-phase. To explain this, we considered the possibility that PCNA content (i.e., the 19A2reactive epitope) peaks during late GI or early S-phase as certain reports have suggested (6,10,11,13 ). Our results confirm this theory with respect to formalin-fixed rat hepatocytes based on the existence of various staining patterns.
Staining patterns could be separated into three general categories. The first category includes nuclei exhibiting intense PCNArelated stain with little or no BrdU content (Figure 3) . Assuming that nuclear PCNA peaks during late GI and early S-phases, cells in that period of the cell cycle at the time of sacrifice would exhibit intense PCNA staining with little or no BrdU present. The second category of stain includes nuclei with weak to strong BrdU staining and little or no PCNA staining (Figure 4) . This category of stain would be consistent with cells in late S-phase at the start of the BrdU pulse dosing. These cells take up BrdU during S-phase and pass almost or completely through the G2 phase of the cell cycle by the time of sacrifice. The duration of S and Gz phases in adult rat hepatocytes has been reported to be 8.4 and 2.7 hr, respectively (17). As BrdU content is not lost at the termination of S-phase, these nuclei would be expected to exhibit weak to strong staining for BrdU, depending on how far into S-phase the cells were at the start of the BrdU dosing. Hepatocytes in G2 phase of the cell cycle demonstrate little to no nuclear PCNA staining ( 5 ) . The third category includes nuclei with intense stain for both antigens (Figure   2 ). This category of stain is consistent with the period during S-phase in which labeling for the two antigens overlaps. Cells in mid-S-phase at the time of sacrifice would exhibit staining for both antigens and, depending on the exact point within S-phase that this occurred, the intensity of the two stains would-vary slightly but would be strong.
From the data presented in 'lkble 1 it is possible to approximate the number of uniform and intense red nuclei in GI and early S-phases. Nuclei positive for only PCNA on dual-stain sections are likely to be in late GI phase. If this number is then compared with the number of PCNA-positive nuclei on single-stain sections, we approximate the percentage of labeled nuclei in GI, with the remainder in early S-phase. As outlined in Table 2 , the percentage of PCNA-labeled nuclei that are in GI phase is 61.6, with the remaining 38.4% in early S-phase. These numbers serve to emphasize the degree of difference between the population of cells labeled by antibodies to BrdU and PCNA in formalin-fixed rat hepatocytes. It should be recognized that some small degree of error is associated with these numerical evaluations, which depend on the sensitivity of the BrdU stain to detect nuclei in very early S-phase and our ability to identlfy intensely and uniformly labeled nuclei.
These data, although demonstrating the differences between PCNA and BrdU, do not eliminate the possibility of using the anti-PCNA antibody to determine a labeling index in formalin-fixed tissues. Indeed, if increases in the entire GI, Gz, and S-phase fraction of cells are proportional to increases in the traditionally evaluated S-phase fraction, then PCNA will still be a powerful tool for quantifying increases in cell proliferation in formalin-fixed tissues. Moreover, evaluating the entire GI, G2, and S-phase growth fraction by including all PCNA-positive nuclei in the evaluation decreases the subjectivity associated with establishing a PCNA S-phase labeling index. Other techniques such as true color image analysis for the chromophores used here and differential emission spectroscopy of fluorophore-conjugated antibodies could further reduce the subjectivity and enable quantitation of label intensity. Alternatively, various fixation techniques, such as methanol vs formalin fixation, that lead to differential destruction of nucleoplasmic PCNA antigenicity may further aid in the separation of S-phase and GI-phase cell fractions (4,9) . Finally, with the dual-stain technique reported here it is possible to study factors affecting changes in cell cycle time by varying the time of BrdU administration and sacrifice. This approach may have utility in studies of cancer chemotherapeutics and theoretical models of carcinogenesis.
